Marksans Pharma’s Subsidiary Relonchem Gains UK MHRA Approval
Filing Summary
Marksans Pharma Ltd announced that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two products: Mefenamic Acid 250 mg and 500 mg Film-Coated Tablets. This authorization allows Relonchem to market these pharmaceutical products in the UK. The announcement was made on November 17, 2025. Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations globally, with facilities approved by leading regulatory agencies.
Marksans Pharma Ltd announced on November 17, 2025, that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA). The authorization pertains to two products: Mefenamic Acid 250 mg Film-Coated Tablets and Mefenamic Acid 500 mg Film-Coated Tablets.
This authorization permits Relonchem to market these pharmaceutical products within the UK. The announcement was communicated to the BSE Limited and the National Stock Exchange of India Limited, with the relevant scrip code and symbol being 524404 and MARKSANS, respectively.
Marksans Pharma Ltd is involved in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets. The company operates manufacturing facilities in India, the USA, and the UK, which are approved by several leading regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. Marksans Pharma’s product portfolio covers major therapeutic segments such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies. The company markets these products globally.